Kura Oncology (NASDAQ:KURA) Raised to “Strong-Buy” at Lifesci Capital

Lifesci Capital upgraded shares of Kura Oncology (NASDAQ:KURA) to a strong-buy rating in a research report report published on Tuesday, Zacks.com reports.

A number of other brokerages also recently weighed in on KURA. HC Wainwright reiterated a “buy” rating and issued a $32.00 price objective on shares of Kura Oncology in a research report on Monday, August 12th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a research report on Monday, September 9th. JMP Securities reissued a “market outperform” rating and set a $32.00 target price on shares of Kura Oncology in a research note on Monday, August 12th. Wedbush reissued an “outperform” rating and set a $37.00 target price on shares of Kura Oncology in a research note on Friday, August 9th. Finally, StockNews.com cut shares of Kura Oncology from a “hold” rating to a “sell” rating in a research note on Thursday, August 22nd. One analyst has rated the stock with a sell rating, one has given a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Kura Oncology has an average rating of “Moderate Buy” and an average target price of $28.83.

Kura Oncology Trading Down 1.5 %

NASDAQ KURA opened at $17.51 on Tuesday. The company has a market capitalization of $1.34 billion, a PE ratio of -7.85 and a beta of 0.84. The company has a fifty day moving average of $19.34 and a 200 day moving average of $20.09. Kura Oncology has a 1 year low of $7.52 and a 1 year high of $24.17. The company has a debt-to-equity ratio of 0.02, a current ratio of 14.94 and a quick ratio of 14.94.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.59) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.04. The firm’s quarterly revenue was up .0% on a year-over-year basis. During the same quarter last year, the company posted ($0.53) earnings per share. Research analysts forecast that Kura Oncology will post -2.46 earnings per share for the current year.

Institutional Trading of Kura Oncology

Large investors have recently bought and sold shares of the business. Susquehanna Fundamental Investments LLC purchased a new stake in Kura Oncology during the 1st quarter valued at about $507,000. Hennion & Walsh Asset Management Inc. grew its stake in Kura Oncology by 42.3% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 181,674 shares of the company’s stock valued at $3,875,000 after acquiring an additional 54,031 shares in the last quarter. Assenagon Asset Management S.A. grew its stake in Kura Oncology by 50.1% during the 2nd quarter. Assenagon Asset Management S.A. now owns 1,731,577 shares of the company’s stock valued at $35,653,000 after acquiring an additional 577,732 shares in the last quarter. Vanguard Group Inc. grew its stake in Kura Oncology by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 4,065,903 shares of the company’s stock valued at $86,726,000 after acquiring an additional 28,212 shares in the last quarter. Finally, Sofinnova Investments Inc. grew its stake in Kura Oncology by 64.4% during the 2nd quarter. Sofinnova Investments Inc. now owns 825,243 shares of the company’s stock valued at $16,992,000 after acquiring an additional 323,303 shares in the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.